The influence of HPMC concentration on release of theophylline or hydrocortisone from extended release mini-tablets

Drug Development and Industrial Pharmacy

Volumn 39, Issue 8, 2013, Pages 1167-1174

  Mohamed, Faiezah A A ^a   Roberts, Matthew ^a   Seton, Linda ^a   Ford, James L ^a   Levina, Marina ^b   Rajabi Siahboomi, Ali R ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b Colorcon Ltd ^*  (United Kingdom)

Author keywords

ER; HPMC; Hydrocortisone; Mini tablets; Paediatric; Theophylline

Indexed keywords

HYDROCORTISONE; HYDROXYPROPYLMETHYLCELLULOSE; THEOPHYLLINE;

ARTICLE; CONCENTRATION (PARAMETERS); DRUG RELEASE; DRUG SOLUBILITY; TABLET FORMULATION; TENSILE STRENGTH;

DELAYED-ACTION PREPARATIONS; HYDROCORTISONE; METHYLCELLULOSE; SOLUBILITY; TABLETS; TENSILE STRENGTH; THEOPHYLLINE;

EID: 84879960531     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.681053     Document Type: Article

References (31)

1. Tomson SA, Tuleu C, Wong ICK, Keady S, Pitt KG, Sutclife AG. (2009). Minitablets: new modality to deliver medicines to preschool-aged children. Pediatrics, 123:235-238.
2. Nunn AJ. (2003). Making medicines that children can take. Arch Dis Child, 88:369-371.
3. Santen E, Barends DM, Frijlink HW. (2002). Breaking of scored tablets: a review. Eur J Pharm Biopharm, 53:139-145.
4. Costello I, Long PF, Wong IK, Tuleu C, Yeung V. (2007). Paediatric Drug Handling, Paediatric Formulations in Practice. London, UK: Pharmaceutical Press.
5. Broadhurst EC, Ford JL, Nunn AJ, Rowe PH, Roberts M. (2008). Dose uniformity of samples prepared from dispersible aspirin tablets for paediatric. Eur J Hosp Pharm, 14:27-31.
6. Breitkrutz J, Wessel T, Boss J. (1999). Dosage form for oral drug adminstration to children. Chapter 13. Introduction to Paediatric and Perinatal Drug Terapy. Updated from Paediatric and Perinatal Drug Terapy. pp. 25-33.
7. Lennartz P, Mielck JB. (1998). Minitabletting: improving the compactability of paracetamol powder mixtures. Int J Pharm, 173:75-85.
8. Lopes CM, Lobo JM, Pinto J F, Costa P. (2006). Compressed mini-tablets as a biphasic delivery system. Int J Pharm, 323:93-100.
9. Lopes CM, Sousa Lobo JM, Costa P, Pinto JF. (2006). Directly compressed mini matrix tablets containing ibuprofen: preparation and evaluation of sustained release. Drug Develop Indus Pharm, 32:95-106.
10. Greenhill LL, Findling RL, Swanson JM. (2002). A double-blind, placebo-controlled study of modifed-release methylphenidate in children with attention-defcit/hyperactivity disorder. Pediatrics, 109:e39.
11. De Haan P, Lerk C F. (1984). Oral controlled release dosage forms. A review. Pharm Weekbl Sci, 6:57-67.
12. Grassi M, Grassi G. (2005). Mathematical modelling and controlled drug delivery: matrix systems. Curr Drug Deliv, 2:97-116.
13. Abdul S, Poddar SS. (2004). A fexible technology for modifed release of drugs: multi layered tablets. J Control Release, 97:393-405.
14. Li CL, Martini LG, Ford JL, Roberts M. (2005). Te use of hypromellose in oral drug delivery. J Pharm Pharmacol, 57:533-546.
15. Debono M, Price JN, Ross RJ. (2009). Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab, 23:221-232.
16. Heames K, Shah U, Riby P, Blair J, Ford J. (2009). Accuracy of 2.5 mg hydrocortisone doses from quatered 10 mg tablets. Endocrine Abstracts, 23:OC3.1.
17. Kotani A, Hashimoto M, Kotani T, Kusu F. (2011). Prepeak of trolox caused by theophylline and its application to the determination of theophylline in rat plasma. J Electroanal Chem, 656:85-90.
18. Simons E. (1985). Guideline for the use of Teophylline in children with asthma. Canada Med Assoc, 132:1011-1012.
19. Stubbs J, Haw C, Dickens G. (2008). Dose form modifcation-a common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients. Int Psychogeriatr, 20:616-627.
20. Seton L, Khamar D, Bradshaw IJ, Hutcheon GA. (2010). Solid state forms of theophylline: presenting a new anhydrous polymorph. Crystal Growth & Des, 10:3879-3886.
21. Fell JT, Newton JM. (1968). Te tensile strength of lactose tablets. J Pharm Pharmacol, 20:657-659.
22. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 15:25-35.
23. Ford JL, Mitchell K, Rowe P, Armstrong DJ, Elliott PNC, Rostron C, Hogan JE. (1991). Mathematical modelling of drug release from hydroxypropyl methylcellulose matrices: efect of temperature. Int J Pharm, 71:95-104.
24. Ford JL, Rubinstein MH, McCaul F, Hogan JE, Edgar PJ. (1987). Importance of drug type, tablet shape and added diluents on drug release kinetics from hydroxypropyl methylcellulose matrix tablets. Int J Pharm, 40:223-234.
25. Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv, 60:110-111.
26. Wan LSC, Heng PWS, Wong LF. (1991). Te efect of hydroxypropyl methylcellulose on water penetration into a matrix system. Int J Pharm, 73:111-116.
27. Tahara K, Yamamoto K, Nishihata T. (1995). Overall mechanism behind matrix sustained release (SR) tablets prepared with hydroxypropyl methylcellulose 2910. J Control Release, 35:59-66.
28. Yang L, Fassihi R. (1997). Examination of drug solubility, polymer types, hydrodynamics and loading dose on drug release behavior from a triple-layer asymmetric confguration delivery system. Int J Pharm, 155:219-229.
29. Fu XC, Wang GP, Liang WQ, Chow MS. (2004). Prediction of drug release from HPMC matrices: efect of physicochemical properties of drug and polymer concentration. J Control Release, 95:209-216.
30. Siepmann J, Peppas NA. (2000). Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the "sequential layer" model). Pharm Res, 17:1290-1298.
31. Siepmann J, Podual K, Sriwongjanya M, Peppas NA, Bodmeier R. (1999). A new model describing the swelling and drug release kinetics from hydroxypropyl methylcellulose tablets. J Pharm Sci, 88:65-72.